CD274 and neoplasm: Immune check inhibitors (ICI) have become a key therapeutic strategy to stimulate the immune anti-cancer response; across various solid tumor malignancies, response to PD-1 or PD-L1 blockade was associated with some tumor-intrinsic (high tumor antigen burden, high neoantigen load) or microenvironmental features (PD-L1 expression, T lymphocyte infiltration).